Topical immunomodulators - Progress towards treating inflammation, infection, and cancer

Lancet Infectious Diseases

Volumn 1, Issue 3, 2001, Pages 189-198

  Hengge, U R ^c   Benninghoff, B ^a   Ruzicka, T ^b   Goos, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b 3M Deutschland GmbH   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; VACCINE;

ACTIVE IMMUNIZATION; ANIMAL; HUMAN; IMMUNOLOGY; INFECTION; INFLAMMATION; INNATE IMMUNITY; NEOPLASM; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; INFECTION; INFLAMMATION; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; VACCINES;

EID: 0035495948     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00095-0     Document Type: Review

References (85)

1. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science. 272:1996;50-53.
2. Stevens D.L., et al. Immune modulatory effects of antibiotics. Curr Opin Infect Dis. 9:1996;165-169.
3. Masihi K.N. Immunomodulatory agents for prophylaxisand therapy of infections. Int J Antimicrob Agents. 14:2000;181-191.
4. Lewis H.M. Topical immunotherapy of refractory warts. Cutis. 12:1973;863-867.
5. Buckley D.A., Keane F.M., Munn S.E., Fuller L.C., Higgins E.M., Du Vivier A.W. Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol. 141:1999;292-296.
6. Lee A.N., Mallory S.B. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. J Am Acad Dermatol. 41:1999;595-599.
7. Massing A.M., Epstein W.L. Natural history of warts: a 2-year study. Arch Dermatol. 87:1963;306-310.
8. Wagner T.L., Horton V.L., Carlson G.L., et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers imiquimod, S-27609 and S-28463. Cytokine. 9:1997;837-845.
9. Imbertson L.M., Beaurline J.M., Couture A.M., et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 110:1998;734-739.
10. Wagner T.L., Ahonen C.L., Couture A.M., et al. Modulation of TH1 and TH2 cytokine production with the immuneresponse modifiers, R-848 and imiquimod. Cell Immunol. 191:1999;10-19.
11. Kono T., Kondo S., Pastore S., et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 13:1994;71-76.
12. Slade H.B., Owens M.L., Tomai M.A., Miller R.L. Imiquimod 5% cream (Aldara™). Exp Opin Invest Drugs. 7:1998;437-449.
13. Arany I., Tyring S.K., Stanley M.A., et al. Enhancement of innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 43:1999;55-63.
14. Testerman T.L., Gerster J.F., Imbertson L.M., et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol. 58:1995;365-372.
15. Burns R.P. Jr, Ferbel B., Tomai M., Miller R., Gaspari A.A. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol. 94:2000;13-23.
16. Suzuki H., Wang B., Shivji G.M., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 114:2000;135-141.
17. Bishop G.A., Hsing Y., Hostager B.S., Jalukar S.V., Ramirez L.M., Tomai M.A. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol. 165:2000;5552-5557.
18. Vasilakos J.P., Smith R.M., Gibson S.J., et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol. 204:2000;64-74.
19. Buates S., Matlashewski G. Identification of genes induced by a macrophage activator, s-28463, using gene expression array analysis. Antimicrob Agents Chemother. 45:2001;1137-1142.
20. Koutsky L.A., Galloway D.A., Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 10:1988;122-163.
21. Gissmann L. Papillomaviruses and human oncogenesis. Curr Opin Genet Dev. 2:1992;97-102.
22. Phelps W.C., Alexander K.A. Antiviral therapy for human papillomaviruses: rationale and prospects. Ann Intern Med. 123:1995;368-382.
23. Alam M., Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 137:2001;337-341.
24. Fazel N., Wilczynski S., Lowe L., Su L.D. Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections. Dermatol Clin. 17:1999;521-536.
25. Gissmann L. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am. 23:1996;625-639.
26. Coleman N., Birley H.D., Renton A.M., et al. Immunological events in regressing genital warts. Am J Clin Pathol. 102:1994;768-774.
27. Edwards L., Ferency A., Eron L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 134:1998;25-30.
28. Tyring S.K., Arany I., Stanley M.A., et al. A randomized,controlled, molecular study of condylomata acuminataclearance during treatment with imiquimod. J Infect Dis. 178:1998;551-555.
29. Beutner K.R., Spruance S.L., Hougham A.J., Fox T.L., Owens M.L., Douglas J.M. Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 38:1998;230-239.
30. Gollnick H., Barasso R., Jappe U., et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS. 12:2001;22-28.
31. Wagman F.A., Estape R.E., Angioli R., Penalver M.A. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls. Obstet Gynecol. 97:(suppl):2001;14.
32. Bishop P.E., McMillan A., Fletcher S. An immunohistological study of spontaneous regression of condylomata acuminata. Genitourin Med. 66:1990;79-81.
33. Arany I., Rady P., Tyring S.K. Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res. 23:1994;131-141.
34. Hengge U.R., Franz B., Goos M. Decline of infectious skin manifestations in the era of highly active antiretroviral therapy. AIDS. 14:2000;1069-1070.
35. Arrese J., Paquet P., Claessens N., Pierard-Franchimont C., Pierard G. Dermal dendritic cells in anogenital warty lesions unresponsiveto an immune-response modifier. J Cutan Pathol. 28:2001;131-134.
36. Hengge U.R., Esser S., Schultewolter T., et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol. 143:2000;1026-1031.
37. Barba A.R., Kapoor S., Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of Molluscum contagiosum in children. Dermatol Online J. 7:2001;20-23.
38. Lampert A., Pauwels C., Duboucher C., et al. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1:1988;795-797.
39. Wieland U., Ritzkowsky A., Stoltidis M., et al. Papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol. 115:2000;124-128.
40. Bouwes Bavinck J.N., Stark S., Petridis A.K., et al. The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated humanpapillomavirus type 8 in patients with actinic keratoses. Br J Dermatol. 142:2000;103-109.
41. Mackenzie-Wood A., Kossard S., de Launey J., Wilkinson B., Owens M.L. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 44:2001;462-470.
42. Davis G., Wentworth J., Richard J. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med. 45:2000;619-623.
43. Hengge U.R., Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol. 137:2001;709-711.
44. Stockfleth E., Meyer T., Benninghoff B., Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol. 144:2001;1050-1053.
45. Beutner K.R., Geisse J.K., Helman D., Fox T.L., Ginkel A., Owens M.L. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 41:1999;1002-1007.
46. Marks R., Gebauer K., Shumack S., Amies M., Bryden J., Fox T.L., et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 44:2001;807-813.
47. Kagy M.K., Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 26:2000;577-578.
48. Steinmann A., Funk J.O., Schuler G., von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 43:2000;555-556.
49. Kim J., Modlin R.L., Moy R.L., et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T-cell immune response. J Immunol. 155:1995;2240-2247.
50. Stockfleth E., Rowert J., Arndt R., Christophers E., Meyer T. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol. 143:2000;846-850.
51. Cutler K., Kagen M.H., Don P.C., McAleer P., Weinberg J.M. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus. Acta Derm Venereol. 80:2000;134-135.
52. Rinne D., Linhart C., Schofer H. Lip papillomatosis in immunodeficiency: therapy with imiquimod. Br J Dermatol. 142:2000;196-197.
53. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis. 179:1999;1485-1494.
54. Goldstein D., Hertzog P., Tomkinson E., et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis. 178:1998;858-861.
55. Gilson R.J., Shupack J.L., Friedman-Kien A.E., et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS. 13:1999;2397-2404.
56. Liota E., Smith K.J., Buckley R., Menon P., Skelton H. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg. 4:2000;76-82.
57. Weisshaar E., Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol. 80:2000;306-307.
58. Pehoushek J., Smith K.J. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol. 137:2001;14-16.
59. Smith K.J., Germain M., Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 27:2001;561-564.
60. Harrison C.J., Miller R.L., Bernstein D.I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother. 38:1994;2059-2064.
61. Bernstein D.I., Harrison C.J., Tomai M.A., Miller R.L. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis. 183:2001;844-849.
62. Christensen B., Hengge U.R. Recurrent urogenital herpes simplex - successful treatment with imiquimod? Sex Transm Infect. 75:1999;132-133.
63. Spruance S.L., Tyring S.K., Smith M.H., Meng T.C. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis. 184:2001;196-200.
64. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am J Med Science. 105:1893;487-511.
65. Shimada S., Yano O., Tokunaga T. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res. 77:1986;808-816.
66. Krieg A.M., Yi A.K., Matson S., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
67. Lipford G.B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol. 165:2000;1228-1235.
68. Stacey K.J., Sester D.P., Sweet M.J., Hume D.A. Macrophage activation by immunostimulatory DNA. Curr Top Microbiol Immunol. 247:2000;41-58.
69. Jakob T., Walker P.S., Krieg A.M., Udey M.C., Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 161:1998;3042-3049.
70. Yi A.K., Peckham D.W., Ashman R.F., Krieg A.M. CpG DNA rescuesB-cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol. 11:1999;2015-2024.
71. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., Thorne P.S., et al. Modulation of airway inflammation by CpG oligodesoxynucleotides in a murine model of asthma. J Immunol. 160:1998;2555-2559.
72. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 162:1999;6284-6293.
73. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 186:1997;1623-1631.
74. Wooldridge J.E., Ballas Z., Krieg A.M., Weiner G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 89:1997;2994-2998.
75. Hacker H., Mischak H., Miethke T., et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17:1998;6230-6240.
76. Davis H.L., Suparto I.I., Weeratna R.R., et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 18:2000;1920-1924.
77. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16:1998;1216-1224.
78. Lipford G.B., Sparwasser T. Hematopoietic remodelingtriggered by CpG DNA. Curr Top Microbiol Immunol. 247:2000;119-129.
79. Sidky Y.A., Borden E.C., Weeks C.E., Reiter M.J., Hatcher J.F., Bryan G.T. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 52:1992;3528-3533.
80. Ahonen C.L., Gibson S.J., Smith R.M., et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol. 197:1999;62-72.
81. Smith J.B., Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murineB-cell lymphoma transplant model. J Natl Cancer Inst. 90:1998;1146-1154.
82. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59:1999;5429-5432.
83. Tighe H., Takabayashi K., Schwartz D., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immu-nogenicity and reduces its allergenicity. J Allergy Clin Immunol. 106:2000;124-134.
84. Schwartz D.A., Wohlford-Lenane C.L., Quinn T.J., Krieg A.M. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 163:1999;224-231.
85. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 166:2001;3451-3457.